Demographic and Clinical Patient Data
| Variable | hsPC (n = 74) | CRPC (n = 74) |
|---|---|---|
| Age at inclusion (y) | 69.9 ± 7.8 (50.0–85.0) | 71.5 ± 7.5 (49.0–85.0) |
| Tracer dose (MBq) | 185.6 ± 20.7 (134.0–300.0) | 184.3 ± 17.1 (149.0–263.0) |
| cfDNA (ng/μL) | 0.745 ± 0.654 (0.0009–4.25) | 1.04 ± 1.42 (0.0818–9.49) |
| PSMA-TV (cm3) | 14.2 ± 76.7 (0.0–659.1) | 175.5 ± 369.2 (0.0–1,597.7) |
| PSMA-positive lesion | ||
| Any lesion | 51 (68.9%) | 64 (86.5%) |
| Prostate lesion | 25 (33.8%) | 19 (25.7%) |
| Lymph node lesion | 26 (35.1%) | 37 (50.0%) |
| Bone lesion | 14 (18.9%) | 48 (64.9%) |
| Organ lesion | 4 (5.4%) | 13 (17.6%) |
| Dominant fraction | ||
| Prostate | 19 (25.7%) | 5 (6.8%) |
| Lymph node | 22 (29.7%) | 19 (25.7%) |
| Bone | 8 (10.8%) | 39 (52.7%) |
| Organ | 2 (2.7%) | 1 (1.4%) |
| PSA (ng/dL)* | 24.98 ± 105.34 (0.09–761.0) | 186.42 ± 618.29 (0.01–3,689.0) |
| Hemoglobin (g/dL)† | 14.06 ± 1.64 (12.1–17.8) | 11.96 ± 1.84 (7.8–15.4) |
| Lactate dehydrogenase (U/L)‡ | 201.21 ± 47.37 (149.0–312.0) | 250.05 ± 229.26 (130.0–1,573.0) |
| Systemic therapies while PET | ||
| Antihormonal therapies | 4 (5.41%) | 55 (78.57%) |
| Cytotoxic therapies | 1 (1.35%) | 3 (16.67%) |
| Systemic therapies after PET | ||
| Local | 24 (55.8%) | 10 (23.3%) |
| Local + ADT | 6 (14.0%) | — |
| ADT | 9 (20.9%) | 14 (32.6%) |
| CHT | 1 (2.3%) | 2 (4.7%) |
| CHT + ADT | 1 (2.3%) | — |
| 177Lu-PSMA | 1 (2.3%) | 16 (37.2%) |
| Study | 1 (2.3%) | 1 (2.3%) |
| Mean follow-up (mo) | 19.8 ± 13.5 (0.0–47.9) | 16.0 ± 14.0 (0.0–49.0) |
↵* n = 14 and 11 data missing in hsPC and CRPC groups, respectively.
↵† n = 59 and 35 data missing in hsPC and CRPC groups, respectively.
↵‡ n = 60 and 36 data missing in hsPC and CRPC groups, respectively.
ADT = androgen deprivation therapy; CHT = concurrent hormone therapy.
Qualitative data are number and percentage; continuous data are mean ± SD and range. Local disease comprised prostate and seminal vesicle lesions.